Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Cancer is a major chronic disease, which can be managed and treated by chemotherapy, radiation therapy, immunotherapy, hormone therapy, stem cell transplant, targeted therapy, and other therapies. Cancer can be treated by using one therapy or by using combination of therapies based on the stage, type of cancer, and other factors. Chemotherapy is the type of treatment, where the drugs are used to stop or slow the growth of cancer cells. Chemotherapy-induced thrombocytopenia is a serious complication in the chemotherapy-treated patients.

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market – Impact of Coronavirus (COVID – 19) Pandemic

The COVID-19 pandemic is expected to restrain the global chemotherapy-induced thrombocytopenia therapeutics market growth during the forecast period. The COVID-19 pandemic and resulting lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare sector has been impacted majorly due to the COVID-19 pandemic. The shutdown has disrupted the supply, distribution, and manufacture of medical supplies globally. Moreover, due to social distancing, the footfall in clinics and health institutions has fallen by over 70% during this pandemic, which has led to decrease in number of chemotherapy procedures, which has negatively impacted the market growth.

Furthermore, the coronavirus pandemic has hampered the development, clinical trials, production, and supply of drugs and other healthcare products and also have affected growth of the healthcare businesses of various companies across the globe. According to the Indian Journal of Medical Sciences, June 6, 2020, the COVID-19 pandemic has affected the conduction of clinical trials due to unavailability of trial site staff, restrictions for travelling, investigational product availability, and others. As a result, the impact of the COVID-19 pandemic is expected to limit growth of the market during the forecast period.

The global chemotherapy-induced thrombocytopenia therapeutics market is estimated to be valued at US$ 1,168.4 million in 2020 and is expected to exhibit a CAGR of 4.5% during the forecast period (2020-2027).

Figure 1: Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Share (%) Analysis, By Drug Class, 2020

Chemotherapy-Induced Thrombocytopenia Therapeutics  | Coherent Market Insights

Increasing incidence of cancer is expected to drive growth of the global chemotherapy-induced thrombocytopenia therapeutics market during the forecast period.

Rising cancer cases is expected to increase the number of chemotherapy procedures and thereby expected to drive the chemotherapy-induced thrombocytopenia therapeutics market growth over the forecast period. For instance, according to the World Cancer Research Fund International’s report in 2018, the total number of cancer cases worldwide was around 17,036,901 in 2018.

According to the same source, the cancer type and new cancer cases in 2018 globally are as follows.

Rank

Cancer Type

New Cases Diagnosed in 2018

1

Lung

2,093,876

2

Breast

2,088,849

3

Colorectal

1,800,977

4

Prostate

1,276,106

5

Stomach

1,033,701

Moreover, rising approvals from regulatory agencies such as the U.S. Food and Drug Administration (FDA) aiding in speedy approval by designating the orphan drug status to drugs targeted to benefit patients with rare disease is expected to boost the market growth. For instance, in December 2019, Dova Pharmaceuticals, Inc., a subsidiary of Swedish Orphan Biovitrum AB received the Orphan Drug Designation grant from the U.S. Food and Drug Administration (FDA) for avatrombopag, a treatment for chemotherapy-induced thrombocytopenia (CIT).

request-sample

Chemotherapy-induced Thrombocytopenia Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 1,168.4 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 4.5% 2027 Value Projection: US$ 1,656.0 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Thrombopoietin Receptor Agonists, Thrombopoietic Agents, Others.
  • By Route of Administration: Oral, Injectable.
  • By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Amgen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Janssen Global Services, LLC (Johnson & Johnson), Partner Therapeutics, Inc., Mission Pharmacal Company, Myelo Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., and Dova Pharmaceuticals, Inc. (Swedish Orphan Biovitrum AB)

Growth Drivers:
  • Increasing number of cancer cases
  • Rising number of Chemotherapy procedures
  • Rising research grants and research activities for drug development
Restraints & Challenges:
  • Lack of approved drugs or therapeutics
  • Clinical trial study failures

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market – Restraints

Lack of approved drugs or therapeutics for the chemotherapy-induced thrombocytopenia is the major factor that is expected to hinder the market growth. Currently, Oprelvekin-recombinant interleukin-11 (IL-11) is the only thrombopoietic agent approved by the U.S. Food and Drug Administration for the treatment of chemotherapy-induced thrombocytopenia. It is indicated for adults with solid tumors and lymphomas associated with severe chemotherapy-induced thrombocytopenia.

Uncertainty of advancement of drug clinical trials and failure of therapeutics is the major factor that is expected to restrain the market growth over the forecast period. For instance, in October 2020, Swedish Orphan Biovitrum AB announced results of its phase III study of Avatrombopag (Doptelet), an oral thrombopoietin (TPO) receptor agonist, in solid tumor cancer patients with chemotherapy-induced thrombocytopenia (CIT). The study failed to meet the primary end point of avoiding platelet transfusions chemotherapy dose reductions by 15% or greater and also failed to show efficacy in chemotherapy-induced thrombocytopenia.

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market – Regional Analysis

On the basis of region, the global chemotherapy-induced thrombocytopenia therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to dominate the global chemotherapy-induced thrombocytopenia therapeutics market during the forecast period, owing to increasing cancer cases in the region. For instance, according to the Cancer Treatment & Survivorship Facts & Figures 2019-2021 Report published by the American Cancer Society, Inc., the estimated number of cancer cases in U.S. was around 16,920,370, as of 1st January 2019.

Moreover, according to the same source, the estimated number of cancer prevalence in the U.S. by cancer type are as follows.


Cancer Type

Male

Cancer Type

Female
January 1, 2019 January 1, 2019 January 1, 2030 January 1, 2030
Prostate 3,650,030 5,017,810 Breast 3,861,520 4,957,960
Colon & rectum 776,120 994,210 Uterine corpus 807,860 1,023,290
Melanoma of the skin 684,470 936,980 Colon & rectum 768,650 965,590
Urinary bladder 624,490 832,910 Thyroid 705,050 989,340
Non-Hodgkin lymphoma 400,070 535,870 Non-Hodgkin lymphoma 357,650 480,690
Leukemia 256,790 352,900 Ovary 249,230 297,580

Figure 2: Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Value (US$ Mn), by Region, 2020

Chemotherapy-Induced Thrombocytopenia Therapeutics  | Coherent Market Insights

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market - Competitive Landscape

Some of the key players operating in the global chemotherapy-induced thrombocytopenia therapeutics market include Amgen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Janssen Global Services, LLC (Johnson & Johnson), Partner Therapeutics, Inc., Mission Pharmacal Company, Myelo Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., and Dova Pharmaceuticals, Inc. (Swedish Orphan Biovitrum)

Chemotherapy-induced thrombocytopenia is a serious complication caused by chemotherapy in the cancer patients. Chemotherapy-induced thrombocytopenia is defined as peripheral platelet count less than 100×109/L, with or without bleeding in cancer patients, which is a serious complication that can lead to chemotherapy dose delays, dose reductions, or discontinuation, and increases the risk of serious bleeding events.

Market Dynamics

Rising cancer cases is the major factor that is expected to drive growth of the global chemotherapy-induced thrombocytopenia therapeutics market during the forecast period. For instance, according to the GLOBOCAN 2018, around 1,412,732 new cancer cases and 672,758 cancer deaths occurred in Latin America and the Caribbean in 2018, where prostate cancer in males and breast cancer in females were the leading cause of cancer death in the region. Moreover, according to the Cancer Research UK, 2015 statistics, 55,122 new cases of breast cancer were registered in 2015, in the U.K. and breast cancer was the most common cancer, accounting for 15% of all new cancer cases in 2015.

Market players are focusing on research and development activities for offering novel products for the treatment chemotherapy-induced thrombocytopenia, which is expected to drive the market growth over the forecast period. For instance, in September 2019, Amgen Inc., initiated Phase III trials, in order to study Romiplostim for chemotherapy-induced thrombocytopenia in adult with gastrointestinal, pancreatic, or colorectal cancer. The study is expected to complete in June 2023.

Key features of the study:

  • This report provides in-depth analysis of the global chemotherapy-induced thrombocytopenia therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global chemotherapy-induced thrombocytopenia therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Amgen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Janssen Global Services, LLC (Johnson & Johnson), Partner Therapeutics, Inc., Mission Pharmacal Company, Myelo Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., and Dova Pharmaceuticals, Inc. (Swedish Orphan Biovitrum)
  • Insights from this report would allow marketers and management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global chemotherapy-induced thrombocytopenia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, chemotherapy-induced thrombocytopenia therapeutics manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global chemotherapy-induced thrombocytopenia therapeutics market.

Detailed Segmentation

  • Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class
    • Thrombopoietin Receptor Agonists
    • Thrombopoietic Agents
    • Others
  • Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration
    • Oral
    • Injectable
  • Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region
    • North America
      • By Country
        • U.S.
        • Canada
      • By Drug Class
        • Thrombopoietin Receptor Agonists
        • Thrombopoietic Agents
        • Others
      • By Route of Administration
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Class
        • Thrombopoietin Receptor Agonists
        • Thrombopoietic Agents
        • Others
      • By Route of Administration
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Class
        • Thrombopoietin Receptor Agonists
        • Thrombopoietic Agents
        • Others
      • By Route of Administration
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Class
        • Thrombopoietin Receptor Agonists
        • Thrombopoietic Agents
        • Others
      • By Route of Administration
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Class
        • Thrombopoietin Receptor Agonists
        • Thrombopoietic Agents
        • Others
      • By Route of Administration
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Class
        • Thrombopoietin Receptor Agonists
        • Thrombopoietic Agents
        • Others
      • By Route of Administration
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Amgen Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Pfizer Inc.
    • Janssen Global Services, LLC (Johnson & Johnson)
    • Partner Therapeutics, Inc.
    • Mission Pharmacal Company
    • Myelo Therapeutics GmbH
    • Jiangsu HengRui Medicine Co., Ltd.
    • Dova Pharmaceuticals, Inc. (Swedish Orphan)

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Key Highlights
    • Regulatory Scenario
    • Product launch/Approvals
    • PEST Analysis
    • Merger and Acquisition Scenario
    • Market Share Analysis
  4. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Supply Side and Demand Side Analysis
    • COVID-19 Impact on the Cancer Treatment
    • COVID-19 Impact on the Chemotherapy
  5. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Thrombopoietin Receptor Agonists
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Thrombopoietic Agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  6. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Injectable
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  7. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Hospitals Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  8. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 - 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • Germany
        • K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 - 2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Amgen Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Novartis
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Janssen Global Services, LLC (Johnson & Johnson)
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Partner Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Mission Pharmacal Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Myelo Therapeutics GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Jiangsu HengRui Medicine Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Dova Pharmaceuticals, Inc. (Swedish Orphan Biovitrum)
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 29 market data tables and 21 figures on "Chemotherapy-induced Thrombocytopenia Therapeutics Market” - Global Forecast to 2027”.

Frequently Asked Questions

The global chemotherapy-induced thrombocytopenia therapeutics market is expected to exhibit a CAGR of 4.5% during the forecast period (2020-2027).
The value of the global chemotherapy-induced thrombocytopenia therapeutics market is estimated to be valued at US$ 1,168.4 million in 2020.
Amgen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Janssen Global Services, LLC (Johnson & Johnson), Partner Therapeutics, Inc., Mission Pharmacal Company, Myelo Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., and Dova Pharmaceuticals, Inc. (Swedish Orphan Biovitrum AB) are some of the prominent players operating in the global chemotherapy-induced thrombocytopenia therapeutics market.
The global chemotherapy-induced thrombocytopenia therapeutics market is expected to be valued at US$ 1,656.0 million in 2027.
North America is the prominent region in the global chemotherapy-induced thrombocytopenia therapeutics market.
Increasing number of cancer cases, rising number of research grants by the regulatory authorities, and rising research and development activities by the market players are some of the key factors driving the global chemotherapy-induced thrombocytopenia therapeutics market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner